Flourish Research Establishes Meaningful Presence in Oncology with Strategic Investment in Valkyrie Clinical Trials
Partnership Broadens Access to Advanced Cancer Clinical Trials and Strengthens Flourish's Presence in Southern California
APEX, N.C., Oct. 6, 2025 /PRNewswire/ -- Flourish Research ("Flourish"), a leading multi-site clinical trial organization focused primarily on cardiovascular, metabolic, neuroscience, and infectious disease therapeutic areas, today announced the partnership with Valkyrie Clinical Trials ("Valkyrie"), a premier network of oncology-focused clinical research sites.
Founded in 2021 by leading medical oncologist Dr. David Berz, Valkyrie provides cutting-edge cancer therapy to a highly diverse patient population and supports sponsors by furthering research in novel therapies and treatments. The company operates three sites in Los Angeles, CA, serving a network of over 200,000 cancer patients.
Reinhold Schulz, CEO of Flourish, commented, "We are delighted to collaborate with Dr. Berz as we enter the oncology market. Valkyrie has achieved remarkable growth and provides deep medical and scientific expertise to an extensive client base, as well as comprehensive access to patients and referral networks. We look forward to continuing this growth story and realizing the vision of accelerating the development of innovative treatments and delivering lifesaving care to patients with unmet needs."
Dr. Berz, Founder and CEO at Valkyrie, commented, "Partnering with Flourish marks an exciting new chapter for Valkyrie as we advance our mission to expand access to the most effective cancer therapies for patients of all backgrounds. We share a common DNA and by utilizing Flourish's national network and infrastructure, we look forward to accelerating our growth and broadening access to innovative oncology trials."
Scott Niehaus, Managing Director at Genstar Capital, which acquired Flourish in 2024, commented, "Dr. Berz and his team have built a highly impressive and innovative business in one of the most attractive areas of clinical research. This marks Flourish's fifth deal under Genstar ownership, continuing our investment behind Reinhold and the Flourish management team as they grow this leading integrated site network nationwide."
Houlihan Lokey served as exclusive financial advisor and Sheppard Mullin provided legal counsel to Valkyrie. Ropes & Gray LLP provided legal counsel to Flourish.
About Flourish Research
Headquartered in Apex, NC, Flourish's network of 30 sites and over 160 investigators conducts studies spanning all phases of clinical trial research. The Company is known for deep medical expertise in several therapeutic areas and a reliable, predictable, and timely patient recruitment experience. With best-in-class technology, quality, and operations systems, Flourish is well-positioned to best serve patients and its biopharma sponsor and CRO clients to advance clinical research in an efficient manner. For additional information on Flourish, please visit our website at https://flourishresearch.com.
About Genstar Capital
Genstar Capital (www.gencap.com) is a leading private equity firm that has been actively investing in high-quality companies for over 30 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Genstar currently has approximately $50 billion of assets under management and targets investments focused on targeted segments of the financial services, software, healthcare, and industrials industries.
Media Contacts:
Genstar Capital
FGS Global
GenstarCapital@fgsglobal.com
Flourish Research
Corporate Communications
CorporateCommunications@FlourishResearch.com
View original content:https://www.prnewswire.com/news-releases/flourish-research-establishes-meaningful-presence-in-oncology-with-strategic-investment-in-valkyrie-clinical-trials-302575385.html
SOURCE Flourish Research